Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Unmet needs in MDS: treating relapse after alloHSCT & TP53-mutated disease

Hege Garelius • 9 Jun 2022
EHA 2022
Myelodysplastic Syndromes

Hege Garelius, MD, Sahlgrenska University Hospital, Göteborg, Sweden, outlines unmet needs in myelodysplastic syndromes (MDS), which include the treatment of patients who relapse following allogeneic hematopoietic stem cell transplantation (alloHSCT), and the management of patients with TP53 mutations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hege Garelius

0:58
Risk stratification in MDS
Hege Garelius • 9 Jun 2022
1:34
Perspectives on the management of low and high-risk MDS
Hege Garelius • 9 Jun 2022
1:48
The impact of ESAs in lower-risk MDS
Hege Garelius • 9 Jun 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals